Science
Coave Therapeutics Showcases Breakthrough In Peptide-Based Conjugated AAV Vectors Using ALIGATERTM Platform In A Late-Breaking Abstract At ESGCT 2024
(MENAFN - GlobeNewsWire - Nasdaq) Coave's proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ...
By: menafn
- Oct 22 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS